Stock Exchange Intimations

• Shilpa Pharma Lifesciences Limited, Received CEP from EDQM for API, Desmopressin
• Intimation of Closure of Trading Window
• Disclosure under Regulation 31 of SEBI (SAST) Regulations,2011 (Pledge)
• Disclosure under Regulation 31 of SEBI (SAST) Regulations,2011 (Pledge)
• Appointment of Dr.Sridevi Khambhampaty, as CEO of Shilpa Biologicals Private Limited
• Release of Non Disposal Undertaking (NDU) by certain identified promoters of the Company
• Submission of NDA to U.S. FDA by Unicycive - 1st Regulatory submissions from CDMO partnered projects
• USFDA Approval for Bortezomib Injection NDA 212782
• Shilpa Medicare announces successful outcome of Phase 3 studies of SMLNUD07 – NorUDCA
• Redemption of “NCD” by “SBPL” and partial redemption of NCD by “SPL”
• Monitoring Agency Report for the quarter ended 30^thJune, 2024
• Board meeting outcome dated 08^thAug 2024
• SML First Indian company to Successfully Complete Phase 1 Clinical Trial for Recombinant Human Albumin (rHA) 20%
• CEP Received from EDQM for SPL API Unit on Ursodeoxycholic Acid
• SPL - Unit - II, Raichur, Karnataka has cleared the COFEPRIS-Mexico GMP inspection
• First international Market Approval for Adalimumab in Morocco
• SPL - Unit 2 Raichur cleared the ANVISA-Brazil GMP inspection
• Allotment of Equity shares by Shilpa Biologicals Pvt. Ltd
• Analysts / Investors’ call 05^thJul 2024
• Important milestone for the CDMO business of Shilpa Medicare Limited 04^thJul 2024
• Type IV DMF (Drug Master File) of recombinant Human Albumin 20% 04^thJune 2024
• Revised Intimation-Revised rating of India Ratings & Research (Ind-Ra)-issued the Long-Term Issuer Rating at ‘IND A+’ 03^rdJul 2024
• Credit Rating of Shilpa Pharma Lifesciences Limited 03^rdJul 2024
• USFDA Inspection Close-out of Bio-Analytical Laboratory, Unit 7 25^thJune 2024
• Keshav Bhutada – Executive Director of SPL & Remuneration to Mr. Madhav Bhutada in Shilpa BiocarePvt Ltd.
• Intimation for Participation in Investor Conference 12^thJune 2024
• Analysts_Investors Call - Call recording 24^thJune 2024
• Clinical trial Announcement for SML 007 14^thMay 2024
• NCLT Order on STPL Merger 03^rdMay 2024
• Launch of Pemetrexed Injection, 100mg/10 ml, 500 mg/50 ml, 1000 mg/100 ml - NDA 18^thApr 2024
• Europe GMP Approval of Shilpa Medicare Ltd. Unit 4, Jadcherla, Telangana 16^thApr 2024
• SE Intimation on Outcome of the meeting of the Securities Issue Committee
• SE intimation for determination of Issue Price
• Declaration of Postal Ballot Results 14 03.24
• Intimation U/R 30 of the SEBI(LODR) Regulations01.03.24
• Intimation UR 30 of the SEBI(LODR) Regulations 26.02.24
• Intimation under Reg 31A (8) ( c)
• Intimation UR Regulation 31A (8) (c) of SEBI (LODR) Regulations, 2015
• Investor Presentation of the Company for the Quarter ended 31 December 2023
• Board Meeting Outcome - 8.2.2024.pdf
• Investor call intimation 06.02.24
• Declaration of Postal Ballot Results 06.02.24
• Intimation UR 30 of the SEBI(LODR) Regulations 06.02.24
• Intimation under Regulation 29(2) Regulations, 2015 05.02.24
• Intimation U/R Regulation 29 of the SEBI (LODR) Regulations
• Intimation UR 30 of the SEBI(LODR) Regulations 27.01.24
• Intimation under Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015
• Europe Approval for Amifampridine Tablets
• Grant of Code “J” for Pemetrexed Injection
• Intimation of closure of Trading Window
• Intimation U/R 30 of the SEBI(LODR) Regulations 12^th Dec, 2023
• Intimation U/R 30 of SEBI (LODR) Regulations 16^th Nov, 2023
• Investors Call Outcome 11^th Nov, 2023
• Intimation under 31A of the SEBI (LODR) Regulations 10^th Nov, 2023
• Board Meeting Outcome 10^th Nov, 2023
• Intimation U/R 30 of the SEBI(LODR) Regulations 10^th Nov, 2023
• Intimation of Board Meeting 03^nd Nov, 2023
• Intimation U/R 30 of the SEBI(LODR) Regulations 02^nd Nov, 2023
• Intimation U/R 30 of the SEBI(LODR) Regulations 17^th Oct, 2023
• Intimation U/R 30 of the SEBI(LODR) Regulations 11^th Oct, 2023
• Intimation of closure of Trading Window
• Voting Results and Scrutinizer Report of 36th Annual General Meeting as per Regulation
• Intimation U/R 30 of the SEBI(LODR) Regulations 01^st Sept, 2023
• Intimation U/R 30 of the SEBI(LODR) Regulations 01^st Sept, 2023
• Declaration of Postal Ballot Results 29^th Aug, 2023
• Declaration of Postal Ballot Results 31^st July, 2023
• Intimation U/R 30 of the SEBI(LODR) Regulations
• Outcome of the meeting of Board of Directors 10^th Aug, 2023
• Intimation under Reg. 30 (LODR)- 31^st July, 2023
• Postal Ballot Notice – Disclosure under Reg.30
• Outcome of the meeting of Board of Directors held on 21^th July 2023
• Intimation under Reg. 30 (LODR)- 04^thJuly, 2023 Newspaper Publication
• Intimation of Closure of Trading Window
• Outcome of the meeting of Board of Directors 23^rd June, 2023
• Outcome of the meeting of Board of Directors 25^th May, 2023
• Prior Intimation uR 29 Final
Intimation U/R of the SEBI ( LODR) Regulations
• Intimation U/R 30 of the SEBI(LODR) Regulations
• Intimation U/R 30 of the SEBI(LODR) Regulations
• Intimation of Board Meeting under Regulation 29 of SEBI
• Intimation under Reg. 30 (LODR)- 11^th Mar, 2023
• Intimation under Reg. 30 (LODR)- 28^th Mar, 2023
• Intimation under Reg. 30 (LODR)- 13^thFeb, 2023
• Intimation under Reg. 30 (LODR)- 15^thFeb, 2023 Inverstors Presentation
• Intimation under Reg. 30 (LODR)- 16^thFeb, 2023
• Intimation under Reg. 30 (LODR)- 21^stFeb, 2023
• Intimation under Reg. 30 (LODR)- 16^thFeb, 2023
• News Paper Publication - 15^thFeb, 2023
• Board Meeting Outcome 14^th Feb, 2023
• Credit Rating
• Intimation under Reg. 30 (LODR) - 10^th Apr, 2023
Intimation under Reg. 30 (LODR)- 16^thDec, 2022
• Intimation under Reg. 30 (LODR)- 30^thNov, 2022
• Intimation under Reg. 30 (LODR)- 21^stNov, 2022
• Intimation under Reg. 30 (LODR)- 17^thNov, 2022
• Intimation under Reg. 30 (LODR)- 14^thNov, 2022 Newspaper Publication
• Intimation under Reg. 30 (LODR)- 13^thNov, 2022
• Intimation under Reg. 30 (LODR)- 12^thNov, 2022
• Intimation under Reg. 30 (LODR)- 03^rdNov, 2022
• Intimation under Reg. 30 (LODR)- 28^thOct, 2022
• Intimation under Reg. 30 (LODR)- 22^ndOct, 2022
• Intimation under Reg. 30 (LODR)- 06^thOct, 2022 Newspaper Publication
• Intimation under Reg. 30 (LODR)- 28^thSep, 2022
• Intimation under Reg. 30 (LODR)- 26^thSep, 2022
• Intimation under Reg. 30 (LODR)- 19^thSep, 2022
• Intimation under Reg. 30 (LODR)- 16^thSep, 2022
• Intimation under Reg. 30 (LODR)- 08^thSep, 2022
• Intimation under Reg. 30 (LODR)- 30^thAug, 2022
• Intimation under Reg. 30 (LODR)- 25^thAug, 2022
• Intimation under Reg. 30 (LODR)- 23^rdAug, 2022
• Intimation under Reg. 30 (LODR)- 19^thAug, 2022
• Intimation under Reg. 30 (LODR)- 13^thAug, 2022
• Intimation under Reg. 30 (LODR)- 12^thAug, 2022
• Intimation under Reg. 30 (LODR)- 11^thAug, 2022
• Intimation under Reg. 30 (LODR)- 27^thJun, 2022
• Intimation under Reg. 30 (LODR) - 31^st May, 22
• Intimation under Reg. 30 (LODR) - 25^th May, 22
• Intimation under Reg. 30 (LODR) - 02^nd May, 22
• Intimation under Reg. 30 (LODR) - 25^th Apr, 22
• Intimation under Reg. 30 (LODR) - 02^nd Apr, 22
• Launch of new brand Capebel (Capecitabine 1000 MG dispersible tablet)
• Outcome of the Investors Analysts meet Dated 14^th Nov, 2022
• Announcement under Reg.30(lodr) Newspaper Publication Dated 13^th Nov, 2022
• Appointment of o3 Capital Global Advisory Private Limited
• Report on Voilation
• Outcome of 35th Annual General Meeting
• Cessation of Directorship of Ms. Sirisha Chintapalli on account of completion of tenure
• Intimation of closure of Trading Window
• Voting Results and Scrutinizer Report of 35th Annual General Meeting
• Intimation of Newspaper Publication - E-voting results of 35th AGM
• Intimation under Reg. 30 (LODR) - 22^nd Sep, 2022
• Intimation under Reg. 30 (LODR) - 19^th Sep, 2022
• Intimation under Reg. 30 (LODR) - 16^th Sep, 2022
• Intimation under Reg.34 and 42 of SEBI (LODR) - Notice of 35^th AGM and Annual Report
• Newspaper Publication of dispatch of Notice of 35^th Annual General Meeting (AGM)
• Book Closure Date and Record Date - 35th AGM
• Clarification with regard to query on shareholding pattern for the quarter ended 30^th Jun, 2022
• Intimation of the Investors Analysts meet scheduled on 24^th Aug, 2022
• Outcome of the Investors Analysts meet dt 24^th Aug, 2022
• Intimation UR 30 - 19^th Aug, 2022
• Book Closure Date & Record Date – 35^th AGM
• Announcement under Reg. 30 (LODR) Newspaper Publication dt.13.08.2022
• Outcome of BM 33, 36 & 42 - 11^th Aug, 2022
• Intimation UR 30 - 29^th Jul, 2022
• Intimation UR 30 - 16^th Jul, 2022
• Intimation UR 30 - 12^th Jul, 2022
• Appointment of Dr Kamal K Sharma as an Additional Independent Director - 1^st July, 2022
• SE Intimation on Slump Sale - 1^st July, 2022
• Trading window closure notice - 1^st July, 2022
• Intimation UR 30 - 27^rd June, 2022
• Board Meeting Outcome to Stock Exchanges 23^rd May, 2022
• Prior Intimation UR 29 16^th May, 2022
• SE intimation on Slump Sale 2^nd April, 2022
• Resignation of CS 16^th March, 2022
• Credit Rating 7^th March, 2022
• Press Release 11^th Fab, 2022
• SE Intimation of Resignation of Directors 09^th Fab, 2022
• Update on slump sale_SE Intimation 09^th Fab, 2022
• INTIMATION UR 30 21^st Jan, 2022
• INTIMATION UR 30 19^th Nov, 2021
• INTIMATION UR 30 24^th Sep, 2021
• Outcome of BM 30 14^th Aug, 2021
• Corrigendum And Update 13^th Aug, 2021
• INTIMATION UR 30 29^th July, 2021
• INTIMATION UR 30 28^th July, 2021
• OUTCOME UR 30 12^th July, 2021
• INTIMATION UR 30 25^nd June, 2021
• INTIMATION UR 30 22^nd June, 2021
• INTIMATION REG 30 28^th May, 2021
• INTIMATION BM 24^th May, 2021
• INTIMATION DIVIDEND 25^th May, 2021
• INTIMATION REG 30 17^th May, 2021
• INTIMATION REG 30 26^th April, 2021
• CLOSURE OF TRADING WINDOW 31^st Mar, 2021
• UR 30 - MEETING UPDATES 31^st Mar, 2021
• INTIMATION UR 30 05^th Mar, 2021
• Intimation Swatchshil 04^th Mar, 2021
• Investor Notification, 18^th Feb, 2021
• INTIMATION UR 30, 18^th Feb, 2021
• INTIMATION REG 30, 15^th Feb, 2021
• INTIMATION REG 30, 13^th Feb, 2021
• CFO Resignation 19^th Jan, 2021
• Closure Of Trading Window 30^th Dec, 2020
• Credit Rating 15^th Dec, 2020
• US FDA 10^th Oct, 2020
• Amit Chander Resignation 02^nd Oct, 2020
• Related Party Transactions U/R 23(9) 30^th Sep, 2020
• Outcome Of BM 09^th Sep, 2020
• Investors Meeting Outcome
• Investors Meeting Intimation
• INTIMATION REG 30
• Outcome Of BM
• Intimation 29
• INTIMATION REG 30
• DECLARATION
• Outcome Of BM
• Intimation 29
• Intimation UR 30
• Outcome Of BM UR 30
• Compliance Certificate Half Year
• Intimation UR 30
• Intimation UR 30 – 18^th April, 2020
• Intimation UR 30 – 6^st April, 2020
• Intimation UR 30 – 1^st April, 2020
• Closure Of Trading Window
• Proceedings OF EGM
• Voting Results
• Facility For Attending Egm
• Intimation Of Record Date Interim Dividend
• Outcome Of BM UR 30 – 6^st March, 2020
• Closure Of Trading Window For Dividend
• Intimation UR 29
• Intimation UR 30 – 26^th Feb, 2020
• Intimation R30
• Intimation R30 - Outcome of Board Meeting
• Stock Exchange Intimation_30 – 08^th Feb, 2020
• Intimation UR 30 – 31^st Jan, 2020
• Intimation UR 30 – 31^st Jan, 2020
• Intimation R30 Pirfenidone
• Intimation R30 Lenvatinib
• Company Upadate Lenvatinib
• Intimation Of UR 29
• BM Intimation Feb 10
• Intimation_UR_30_ 04-12-2019
• Outcome of Board meeting_09-11-2019
• Board meeting Intimation_09-11-2019
• Intimation_UR_30_ 25-10-2019
• Intimation U/R 30 on 05-10-2019_sw
• Book Closure Intimation 31^stAGM
• Scrutinizers Report 31^stAGM
• E-Voting Results 30^thAGM
• Scrutinizer Report 30^thAGM

• Intimation U/R 30 SEBI(LODR) 07.09.2019
• Intimation U/R 30 on 16-05-2019 sw
• Intimation U/R 30 on 17-05-2019 sw
• Intimation U/R 30 of the SEBI(LODR) Regulations- Reg. - (USFDA ANDA sw)
• Intimation U/R 30 of the SEBI(LODR) Regulations- Reg. - (USFDA Voluntary action initiated sw)
• Intimtion under regulation 30 SEBI (LODR) 2015
• Outcome under regulation 30 SEBI (LODR) 2015 on 07th Feb 2019
• BSE-Intimation of BM on 13th Feb 2018
• BSE-Intimation of BM on 29th May 2017
• BSE-Intimation of BM on 9th March 2017
• BSE-Record Date on 6th March 2017
• BSE-Intimation of BM on 06th March 2017
• BSE-Intimation of BM on 31st Jan 2017
• BSE-Intimation of BM on 17th Aug 2016
• NSE-Intimation of BM on 17th Aug 2016